Defunct Company
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
355
NCT04862767
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 9, 2021
Completion: Aug 21, 2023
NCT04856969
Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
Start: Mar 30, 2021
Completion: May 4, 2021
NCT05017987
Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012
Start: Jun 19, 2021
Completion: Jul 12, 2021
NCT05573477
Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
Phase: Phase 3
Start: Nov 16, 2022
Completion: Jun 30, 2024
NCT06933524
Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors
Start: Dec 1, 2025
Completion: Dec 1, 2028